Tradipitant
Sponsors
Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals, Xiao Jing (Iris) Wang
Conditions
Atopic DermatitisCoronavirus InfectionDiabetic GastroparesisFunctional DyspepsiaGastroparesisHealthy VolunteerHealthy VolunteersIdiopathic Gastroparesis
Phase 1
Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects
CompletedNCT02621385
Start: 2015-11-30Updated: 2016-04-27
Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers
CompletedNCT04849559
Start: 2021-02-01End: 2021-09-24Updated: 2024-04-16
Phase 2
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
CompletedNCT02651714
Start: 2016-01-19End: 2017-08-04Updated: 2024-06-13
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
CompletedNCT03772340
Start: 2018-12-20End: 2019-06-27Updated: 2025-05-09
Tradipitant for Functional Dyspepsia
Enrolling by invitationNCT05653310
Start: 2023-02-09End: 2027-03-01Target: 60Updated: 2026-07-16
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
CompletedNCT06804603
Start: 2025-02-25End: 2025-10-06Updated: 2025-11-12
Phase 3
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
CompletedNCT03568331
Start: 2018-07-09End: 2019-12-27Updated: 2024-05-13
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
CompletedNCT04028492
Start: 2019-08-20End: 2025-02-21Updated: 2025-07-24
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
TerminatedNCT04140695
Start: 2019-10-21End: 2020-10-14Updated: 2024-05-14
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
Enrolling by invitationNCT04326426
Start: 2020-04-13End: 2020-08-31Target: 300Updated: 2020-04-20
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
CompletedNCT04327661
Start: 2021-11-15End: 2023-04-12Updated: 2024-12-11
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
CompletedNCT05903924
Start: 2023-09-09End: 2024-04-24Updated: 2025-04-04
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Active, not recruitingNCT06138613
Start: 2023-02-27End: 2027-12-30Updated: 2026-04-16
A MULTICENTER OPEN LABEL 3 MONTH SAFETY STUDY WITH TRADIPITANT IN PATIENTS WITH IDIOPATHIC OR DIABETIC GASTROPARESIS
RecruitingCTIS2023-503802-35-00
Start: 2023-11-29Target: 70Updated: 2025-11-13
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
RecruitingNCT06836557
Start: 2024-01-09End: 2025-12-31Target: 100Updated: 2025-02-20
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
RecruitingNCT07446439
Start: 2026-03-27End: 2026-12-01Target: 280Updated: 2026-04-20